Ultra Market Research | Germany EGFR and HER2 Targeted NSCLC Market
Germany EGFR and HER2 Targeted NSCLC Market
Report ID : 866
Category : Germany,Healthcare-Companies
No Of Pages : 133
Published on: November 2024
Status: Published
Format :
Key Question Answer
Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
Introduction
The Germany EGFR & HER2 targeted NSCLC market is rapidly evolving, driven by advancements in oncology treatment and a growing focus on precision medicine. EGFR (Epidermal Growth Factor Receptor) and HER2 (Human Epidermal Growth Factor Receptor 2) targeted therapies are integral in treating non-small cell lung cancer (NSCLC), which constitutes approximately 85% of all lung cancer cases. These therapies offer tailored treatments, enhancing survival rates and reducing side effects. In Germany, the market benefits from cutting-edge research and robust healthcare infrastructure, supporting innovation and adoption. Recent trends emphasize combination therapies and biomarker-based treatments, aligning with personalized medicine goals. As the prevalence of NSCLC increases, particularly among an aging population, the demand for Germany EGFR & HER2 targeted NSCLC solutions continues to surge, underpinned by a favorable regulatory landscape.
Diagnostics and Biomarker Testing Liquid Biopsies Circulating Tumor DNA (ctDNA) Tests Protein Biomarker Panels Others Tissue Biopsies Companion Diagnostic Kits
End Users
Hospitals and Cancer Treatment Centers Diagnostic Laboratories Research Institutes Pharmaceutical and Biotech Companies
List of Market Players
AstraZeneca (United Kingdom)
Roche (Switzerland)
Novartis (Switzerland)
Pfizer (United States)
Merck & Co. (United States)
Boehringer Ingelheim (Germany)
Bayer AG (Germany)
Eli Lilly and Company (United States)
Amgen Inc. (United States)
Sanofi (France)
GlaxoSmithKline (United Kingdom)
Bristol-Myers Squibb (United States)
Daiichi Sankyo (Japan)
Takeda Pharmaceutical (Japan)
AbbVie Inc. (United States)
Drivers
The Germany EGFR & HER2 targeted NSCLC market is propelled by several factors. A primary driver is the rising prevalence of NSCLC, exacerbated by smoking and environmental pollutants. Germany's advanced healthcare infrastructure supports early cancer detection and treatment, increasing the adoption of targeted therapies. The surge in precision medicine practices enhances the market as clinicians adopt biomarker-based treatment plans for improved outcomes. Favorable regulatory frameworks, government funding for oncology research, and strong support for clinical trials accelerate new product approvals. Additionally, growing awareness among patients and healthcare providers about the benefits of targeted therapies fosters demand. Advances in molecular diagnostics, such as liquid biopsies, further enable the precise identification of EGFR and HER2 mutations, boosting therapy efficacy and market growth.
Restraints
Despite its potential, the Germany EGFR & HER2 targeted NSCLC market faces challenges. The high cost of targeted therapies limits accessibility for many patients, particularly in non-urban regions. Stringent regulatory processes, while ensuring safety, can delay the introduction of innovative products. Additionally, resistance to EGFR and HER2 therapies remains a significant concern, leading to relapse or disease progression in some patients. Limited awareness among certain patient populations about the availability and benefits of these therapies also hampers adoption. Moreover, the requirement for specialized diagnostic tests, often costly and not widely available, creates bottlenecks in treatment initiation. Competition from alternative therapies, such as immunotherapies, further pressures market expansion.
Opportunities
Opportunities in the Germany EGFR & HER2 targeted NSCLC market abound, particularly with the growing emphasis on personalized medicine. Expanding clinical research on combination therapies, including EGFR/HER2 inhibitors with immunotherapies, opens new avenues for treatment. Advances in liquid biopsy technology promise quicker, less invasive diagnostic solutions, driving early intervention rates. Collaborations between pharmaceutical companies and research institutes in Germany foster innovation, accelerating the development of novel therapies. Emerging trends in next-generation sequencing (NGS) and artificial intelligence in diagnostics present lucrative opportunities for market players to refine treatment pathways. Furthermore, the focus on healthcare reimbursement policies can enhance patient access to high-cost therapies, expanding the market.
Trend
The Germany EGFR & HER2 targeted NSCLC market is witnessing transformative trends. The integration of artificial intelligence in diagnostic workflows has streamlined biomarker identification, enhancing treatment precision. Another significant trend is the increasing use of real-world data to assess therapy effectiveness and guide regulatory decisions. Germany’s healthcare providers are embracing digital platforms for remote monitoring of NSCLC patients on EGFR/HER2 therapies, ensuring compliance and early identification of resistance. Additionally, the rise of multi-modal therapies, combining targeted drugs with immunotherapies or chemotherapy, is reshaping treatment paradigms. The focus on sustainability in drug manufacturing is another trend, reflecting broader environmental goals.
Approved Products
Tagrisso (AstraZeneca)
Iressa (AstraZeneca)
Herceptin (Roche)
Perjeta (Roche)
T-DM1/Kadcyla (Roche)
Pipeline/Registered/Pre-Registered Products
Amivantamab (Janssen Pharmaceuticals)
Lazertinib (Yuhan Corporation/Janssen)
Poziotinib (Spectrum Pharmaceuticals)
Pyrotinib (Hengrui Pharmaceuticals)
Mobocertinib (Takeda Pharmaceuticals)
Key Target Audience
Oncology Clinics
Research and Academic Institutions
Pharmaceutical and Biotech Companies
Diagnostic Laboratories
Government and Private Healthcare Agencies
FAQs
These are treatments designed to target specific mutations or overexpressions in the EGFR and HER2 proteins, improving outcomes for NSCLC patients.
Germany's robust healthcare infrastructure, advanced research capabilities, and focus on precision medicine drive the market.
High costs, resistance to therapies, and limited access to advanced diagnostics hinder expansion.
Tagrisso, Iressa, and Herceptin are leading approved therapies in Germany.
Biomarkers enable precise identification of eligible patients for EGFR/HER2 therapies, enhancing treatment outcomes.
Table 13: Key Target Audiences for Market Research Reports
Research Methodology
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings Internal and external proprietary databases, relevant patent and regulatory databases National government documents, statistical databases and market reports News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process Middle Circle Represents – Source of Information Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc. Helps in validating and strengthening the secondary research findings Further develops the analysis team’s expertise and market understanding Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers Purchasing managers, technical personnel, distributors and resellers Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment Macro-economic indicators: GDP, etc. Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities. Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of Global market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps:
2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach. 2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of Germany EGFR & HER2 Targeted NSCLC Market and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue Globally. Regional average price has been considered while breaking down this market by application in each region.
This report provides market size of Germany EGFR & HER2 Targeted NSCLC Market for the past year and forecasts for the next six years. Germany EGFR & HER2 Targeted NSCLC Market size is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different Germany EGFR & HER2 Targeted NSCLC Market categories. Market size and forecasts for each major application is provided in the context of Global market. The numbers provided in this report are derived on the basis of demand for Global Skincare Treatment from different application industries in different regions.
